| 1.476 0.016 (1.1%) | 11-29 10:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.91 | 1-year : | 2.17 |
| Resists | First : | 1.63 | Second : | 1.86 |
| Pivot price | 1.4  |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.48  |
MA(20) : | 1.46 |
| MA(100) : | 2.17 |
MA(250) : | 3.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.1 |
D(3) : | 33.5 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 10.94 | Low : | 1.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPSC ] has closed below upper band by 29.6%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.44 - 1.46 | 1.46 - 1.47 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Thu, 09 Nov 2023
Century Therapeutics, FUJIFILM Cellular Dynamics Expand Cell ... - Contract Pharma
Thu, 09 Nov 2023
Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results - Yahoo Finance
Sun, 09 Jul 2023
Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 10% this week, taking one-year losses to 70% - Simply Wall St
Wed, 12 Apr 2023
Century Therapeutics CEO Lalo Flores steps down (NASDAQ:IPSC) - Seeking Alpha
Wed, 08 Feb 2023
Century Therapeutics Announces First Patient Dosed in First-In ... - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 2.166e+007 (%) |
| Held by Institutions | 37.7 (%) |
| Shares Short | 684 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1554e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 368.9 % |
| Return on Equity (ttm) | -17.6 % |
| Qtrly Rev. Growth | 2.49e+006 % |
| Gross Profit (p.s.) | -124.41 |
| Sales Per Share | -62.59 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.3 |
| Dividend | 0 |
| Forward Dividend | 842910 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|